Willingness to pay for a quality-adjusted life-year: The individual perspective

Value in Health

Volumn 13, Issue 8, 2010, Pages 1046-1055

  Bobinac, Ana ^a   Van Exel, N J A ^a   Rutten, Frans F H ^a   Brouwer, Werner B F ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

cost effectiveness; individual preferences; QALY; resource allocation; WTP

Indexed keywords

ADULT; ARTICLE; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; INCOME; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; VISUAL ANALOG SCALE;

EID: 78650155688     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00781.x     Document Type: Article

References (66)

1. Johannesson M, Meltzer D,. Editorial: some reflections on cost-effectiveness analysis. Health Econ 1998; 7: 1-7.
2. McCabe C, Claxton K, Culyer A,. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26: 733-44.
3. Devlin N, Parkin D,. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-52.
4. Shiroiwa T, Sung Y, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2009; 19: 422-37.
5. Appleby J, Devlin N, Parkin D,. NICE's cost effectiveness threshold. BMJ 2007; 335: 358-9.
6. Culyer AJ,. Introduction. In:, Towse A, Pritchard C, Devlin N, eds. Cost-Effectiveness Threshold: Economic and Ethical Issues. London: King's Fund and Office of Health Econ, 2002: 9-15.
7. Culyer AJ, McCabe CJ, Briggs AH, et al. Searching for a threshold not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy 2007; 12: 56-8.
8. Rawlins MD, Culyer AJ,. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224-7.
9. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28.
10. Dolan P, Edlin R,. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis? J Health Econ 2002; 21: 827-43.
11. Hammitt JK,. QALY versus WTP. Risk Anal 2002; 22: 985-1001.
12. Gyrd-Hansen D,. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005; 23: 423-32.
13. Smith RD, Richardson J,. Can we estimate the "social" value of a QALY? Four core issues to resolve. Health Policy 2005; 74: 77-84.
14. Van Houtven G, Powers J, Jessup A, Yang J,. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ 2006; 15: 775-95.
15. Pinto-Prades JL, Loomes G, Brey R,. Trying to estimate a monetary value for the QALY. J Health Econ 2009; 28: 553-62.
16. Bleichrodt H, Quiggin J,. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ 1999; 18: 681-708.
17. Dolan P, Shaw R, Tsuchiya A, Williams A,. QALY maximisation and people's preferences: a methodological review of the literature. Health Econ 2005; 14: 197-208.
18. O'Brien B, Gafni A,. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996; 16: 288-99.
19. Weinstein MC,. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46: 343-5.
20. Gyrd-Hansen D,. Willingness to pay for a QALY. Health Econ 2003; 12: 1049-60.
21. King JT Jr, Tsevat J, Lave JR, Roberts MS,. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005; 25: 667-77.
22. Byrne MM, O'Malley K, Suarez-Almazor M,. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 2005; 25: 655-66.
23. Jansen SJT, Stiggelbout AM, Wakker PP, et al. Unstable preferences: a shift in valuation or an effect of the elicitation procedure? Med Decis Making 2000; 20: 62-71.
24. Smith RD,. The relative sensitivity of willingness-to-pay and time-trade-off to changes in health status: an empirical investigation. Health Econ 2001; 10: 487-97.
25. Donaldson C, Shackley P, Abdalla M, Miedzybrodzka Z,. Willingness to pay for antenatal carrier screening for cystic fibrosis. Health Econ 1995; 4: 439-52.
26. Donaldson C, Shackley P, Abdalla M,. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 1997; 6: 145-59.
27. Donaldson C, Thomas R, Torgerson D,. Validity of open-ended and payment scale approaches to eliciting willingness to pay. App Econ 1997; 29: 79-84.
28. Olsen JA, Donaldson C,. Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Soc Sci Med 1998; 46: 1-12.
29. Gibb S, Donaldson C, Henshaw R,. Assessing strength of preference for abortion method using willingness to pay. J Adv Nurs 1998; 27: 30-6.
30. Dubourg WR, Jones-Lee MW, Loomes G,. Imprecise preferences and survey design in contingent valuation. Economica 1997; 64: 681-702.
31. Bhatia MR, Fox-Rushby JA,. Willingness to pay for treated mosquito nets in Surat, India: the design and descriptive analysis of a household survey. Health Policy Plan 2002; 17: 402-11.
32. Bhatia MR, Fox-Rushby JA,. Validity of willingness to pay: hypothetical versus actual payment. Appl Econ Lett 2003; 10: 737-40.
33. Johnson R, Banzhaf MR, Desvousges WH,. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format, stated-preference approach. Health Econ 2000; 9: 295-317.
34. Blomquist G, Blumenschein K, Johannesson M,. Eliciting willingness to pay without bias using follow-up certainty statements: comparisons between probably/definitely and a 10-point certainty scale. Environ Resour Econ 2009; 43: 473-502.
35. Arrow K, Solow R, Portney P, et al. Report of the NOAA Panel on contingent valuation. Fed Reg 1993; 58: 4602-14.
36. Smith RD,. It's not just what you do, it's the way that you do it: the effect of different payment card formats and survey administration on willingness to pay for health gain. Health Econ 2006; 15: 281-93.
37. Blumenschein K, Johannesson M, Yokoyama KK, Freeman PR,. Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. J Health Econ 2001; 20: 441-57.
38. Poe G, Clark JE, Rondeau D, Schulze WD,. Provision point mechanisms and field validity tests of contingent valuation. Environ Resour Econ 2002; 23: 105-31.
39. Bateman IJ, Jones AP,. Contrasting conventional with multi-level modeling approaches to meta-analysis: expectation consistency in U.K. woodland recreation values. Land Econ 2003; 79: 235-58.
40. Kind P, Dolan P, Gudex C, Williams A,. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-41.
41. Lamers LM, McDonnell J, Stalmeier PF,. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15: 1121-32.
42. CBS. Available from: [Accessed March 21, 2009.
43. Zethraeus N,. Willingness to pay for hormone replacement therapy. Health Econ 1998; 7: 31-8.
44. Mason H, Jones-Lee M, Donaldson C,. Modelling the monetary value of a QALY: a new approach based on UK data. Health Econ 2008; 18: 933-50.
45. EUROVAQ project. Available from: [Accessed May 27, 2009.
46. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis. Br J Dermatol 1999; 141: 1067-75.
47. Parkin D, Devlin N,. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ 2006; 15: 653-64.
48. Brouwer WBF, Van Exel NJA, Baker R, Donaldson C,. The new myth: the social value of the QALY. Pharmacoeconomics 2008; 26: 1-4.
49. Whynes DK, Wolstenholme JL, Frew EJ,. Evidence of range bias in contingent valuation payment scales. Health Econ 2004; 13: 183-90.
50. Frew EJ, Whynes DK, Wolstenholme J,. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med Decis Mak 2003; 23: 150-9.
51. OECD statistics. Available from: [Accessed April 2, 2009.
52. Holland J, Van Exel NJA, Schut FT, Brouwer WBF,. Some pain, no gain. Experiences with the no-claim rebate in the Dutch health care system. Health Econ Policy Law 2009; 4: 405-24.
53. Skjoldborg US, Gyrd-Hansen D,. Conjoint analysis. The cost variable: an Achilles' heel? Health Econ 2003; 12: 479-91.
54. Carson RT,. Contingent valuation: a user's guide. Environ Sci Technol 2000; 34: 1413-8.
55. Blumenschein K, Blomquist GC, Johannesson M, et al. Eliciting willingness to pay without bias: evidence from a field experiment. Econ J 2008; 118: 114-37.
56. RVZ. Available from: [Accessed June 12, 2009.
57. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-42.
58. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008; 4: 349-59.
59. Dolan P, Olsen JA, Menzel P, Richardson J,. An inquiry into the different perspectives that can be used when eliciting preferences in making. Health Econ 2003; 12: 545-51.
60. Stolk EA, Van Donselaar G, Brouwer WBF, Van Busschbach JJ,. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics 2004; 22: 1097-107.
61. NICE. Guide to the Methods of Technology Appraisal. 2004 (reference N0515, Available from: [Accessed April 27, 2009.
62. NICE. Appraising life extending, end of life treatments. 2008. [Accessed July 20, 2009.
63. Towse A,. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 2009; 338: 181.
64. Williams A, Cookson R,. Equity in Health. Handbook of Health Economics., Culyer AJ, Newhouse JP, eds. North Holland, Amsterdam: Handbook of Health Economics, 2000.
65. Brouwer WBF, Culyer AJ, Van Exel NJA, Rutten FFH,. Welfarism vs. extra-welfarism. J Health Econ 2008; 2: 325-38.
66. Baker R, Chilton S, Jones-Lee M, Metcalf H,. Valuing lives equally: defensible premise or unwarranted compromise? J Risk Uncertain 2008; 36: 125-38.